Interestingly, CAML size differs in relation to treatment status; higher pre- and post-treatment CAML sizes in esophageal cancer and non-small cell lung carcinoma (NSCLC) have been correlated to worsened overall survival, possibly related to more aggressive disease subtypes [86,87]. This evidence concerns the gene CAMLG and esophageal cancer.